The representative protein expression of C10orf10 in pairs of BC and corresponding noncancerous breast tissues.

<p>Immunohistochemistry analysis of C10orf10 expression in 75 tumor and corresponding noncancerous samples, and C10orf10 is expressed in epithelial cells of corresponding noncancerous breast tissues (mainly expressed in the cytoplasm, and also mildly expressed in some part of the nucleus). C10orf10 expression is decreased in most BC tissues compared to corresponding noncancerous breast tissues. Immunohistological staining was performed with an anti-C10orf10 antibody, and scale bars are 100 µm.</p

Low expression of C10orf10 is correlated with shorter survival in patients from KM plotter with luminal A, luminal B, Her2+ and grade 2 of the breast cancer.

<p>(A) Kaplan-Meir survival analysis of C10orf10 in 504 patients with luminal A tumors. Auto select best cutoff was chosen in the analysis; Cutoff value used was 1117; Expression range of the probe was 186–3881. (B) Kaplan-Meir survival analysis of C10orf10 in 319 patients with luminal B tumors. Auto select best cutoff was chosen in the analysis; Cutoff value used was 1052; Expression range of the probe was 181–3158. (C) Kaplan-Meir survival analysis of C10orf10 in 88 patients with Her2+ tumors. Auto select best cutoff was chosen in the analysis; Cutoff value used was 655; Expression range of the probe was 153–3475. (D) Survival analysis of C10orf10 expression in 286 patients with grade 2 of the breast cancer. Auto select best cutoff was chosen in the analysis; Cutoff value used was 1117; Expression range of the probe was 143–3859.</p

Low expression of C10orf10 is correlated with shorter survival in BC patients from KM plotter with ER positive and lymph node negative.

<p>(A) Survival analysis of C10orf10 expression in 377 BC patients with ER positive. Auto select best cutoff was chosen in the analysis; Cutoff value used was 1117; Expression range of the probe was 143–3356. (B) Survival analysis of C10orf10 expression in 424 BC patients with lymph node negative. Auto select best cutoff was chosen in the analysis; Cutoff value used was 923; Expression range of the probe was 143–3356.</p

Low C10orf10 expression is correlated with shorter survival in BC patients.

<p>(A) Survival analysis of C10orf10 protein expression in 100 BC patients by Kaplan-Meier survival curve. Tissue array analysis was performed in 100 cases of patients with the survival information. The patients with low expression had a poorer overall survival than those with high expression; HR, hazard ratio; low, staining negative and weak; high, staining moderate and strong. (B) Survival analysis of C10orf10 expression in 100 BC patients by multivariate Cox regression. The C10orf10 expression is an independent prognostic factor. (C) Kaplan-Meir survival analysis of C10orf10 mRNA in 1115 BC patients with Kaplan-Meier Plotter (<a href="http://kmplot.com/analysis/index" target="_blank">http://kmplot.com/analysis/index</a>). The overall survival was longer in the <i>C10orf10</i> high expression group than in the <i>C10orf10</i> low expression group. Auto select best cutoff was chosen in the analysis; Cutoff value used was 1086; Expression range of the probe was 143–3881. (D) Kaplan-Meir survival analysis of C10orf10 mRNA in 3455 BC patients with Kaplan-Meier Plotter. The relapse-free survival was longer in the <i>C10orf10</i> high expression group than in the <i>C10orf10</i> low expression group. Auto select best cutoff was chosen in the analysis; Cutoff value used was 1088; Expression range of the probe was 32–5515.</p

The mRNA expression of C10orf10 is frequently decreased in human BC tissues.

<p>(A) RT-PCR analysis of C10orf10 mRNA levels in normal breast and BC tissues. The β-actin was used as an internal control. (B) C10orf10 mRNA levels was also detected by qRT-PCR analysis in normal breast and BC tissues. The β-actin was used as an internal control. Error bars indicate s.d. (n = 3).</p

Correlations of C10orf10 expression with clinicopathologic features of BC patients.

<p>Correlations of C10orf10 expression with clinicopathologic features of BC patients.</p